Mineralys Shares Jump 43% After Positive Phase 2 Explore-CKD Results

Introduction to MINERALYS THERAPEUTICS INC

MINERALYS THERAPEUTICS INC (ticker: MLYS) is a clinical-stage biopharmaceutical company listed on the Nasdaq Stock Market (exchange: NAS). On September 2, 2025, MLYS shares closed at $22.1720, reflecting a percentage increase of 43.23% on a trading volume of 204,501 shares. The company develops therapies targeting aldosterone-driven cardio-renal-metabolic diseases, with its lead candidate, lorundrostat (MLS-101), advancing through pivotal trials for hypertension and chronic kidney disease.

Corporate Structure and Leadership

Founded in 2019 and headquartered in Radnor, Pennsylvania, Mineralys employs between 51 and 200 staff, according to its LinkedIn profile. The leadership team includes:
• Eric Warren, R.Ph., Chief Commercial Officer, who has experience at Esperion Therapeutics with approximately 30 years in the cardio-metabolic pharmaceutical sector;
• Jessica Ibbitson, Senior Vice President of Clinical Operations, formerly with Vertex Pharmaceuticals and ProQR Therapeutics;
• Michael Tortorici, PharmD, PhD, Senior Vice President of Translational Medicine, with over 17 years in clinical pharmacology;
• Brian Taylor "BT" Slingsby, M.D., Ph.D., M.P.H., Founder and Managing Director at Catalys Pacific;
• Glenn P. Sblendorio, former CEO and CFO at multiple biotech companies, serving on the board.

Hypertension by Jair Lázaro

Recent Developments and News

On June 17, 2025, Mineralys announced topline data from its Phase 2 Explore-CKD trial. This randomized, double-blind, placebo-controlled crossover study involved 59 subjects with hypertension and chronic kidney disease (CKD), where lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic automated office blood pressure and a placebo-adjusted 7.5 mmHg decline (p = 0.0024) after four weeks. The trial also demonstrated a 31% reduction in urine albumin-to-creatinine ratio (p < 0.0001) and a safety profile consistent with existing renin-angiotensin-aldosterone pathway inhibitors.

On May 24, 2025, detailed results from the Phase 3 Launch-HTN trial were shared at the European Society of Hypertension meeting in Italy, with findings indicating efficacy in over 1,000 patients with uncontrolled or resistant hypertension. Earlier, in April 2025, results from the Advance-HTN pivotal trial were published in the Journal of the American Medical Association.

Following the June and May presentations, Mineralys hosted an earnings call to review its second quarter 2025 results after market close on August 12, 2025, and filed its Form 10-Q on the same date.

Financial and Strategic Analysis

MLYS’s share price movement on September 2, 2025, aligns with investor expectations regarding an NDA submission, supported by a core data package including results from the Launch-HTN, Advance-HTN, and Explore-CKD trials. As of August 14, 2025, SEC Schedule 13G/A filings indicate that entities connected to Catalys Pacific Fund hold 13.5% of outstanding shares, while Andera Partners, BioDiscovery 6 FPCI, and Stéphane Bergez collectively own 4.2%.

The company’s strategy focuses on completing pivotal trials, obtaining regulatory approval for lorundrostat, and employing a personalized medicine approach for patients with dysregulated aldosterone. Mineralys has also initiated open-label extension studies and combination trials in chronic kidney disease and obstructive sleep apnea populations, potentially addressing a market of 15 to 20 million Americans with untreated hypertension despite multiple medications.

Market Position and Industry Context

Hypertension affects an estimated 1.28 billion adults globally. Approximately 30% of hypertensive patients exhibit aldosterone dysregulation, a mechanism not directly addressed by existing therapies. Mineralys’s lorundrostat is positioned as a first-in-class aldosterone synthase inhibitor aiming to target this gap, especially within treatment-resistant and comorbid CKD and obstructive sleep apnea populations. The company operates in a competitive antihypertensive market but distinguishes itself with a focus on precision medicine and a robust pipeline of randomized, placebo-controlled studies.

tl;dr

On June 17, 2025, Phase 2 Explore-CKD data indicated significant reductions in blood pressure and albuminuria associated with lorundrostat. Data from the Launch-HTN trial was presented on May 24, 2025, and the Advance-HTN trial results were published in April 2025, completing the data package for an NDA submission. MLYS shares increased by 43.23% to $22.1720 on September 2, 2025. Institutional ownership exceeds 17% combined, reflecting investor confidence preceding regulatory submissions and potential market introduction.